Patents by Inventor Walter A. Blattler

Walter A. Blattler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9605070
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 28, 2017
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Publication number: 20150259420
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20150218274
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Publication number: 20150210769
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20150110816
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 23, 2015
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Ralph SCHWALL
  • Publication number: 20140212411
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., IMMUNOGEN, INC.
    Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
  • Publication number: 20140154804
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 5, 2014
    Applicant: IMMUNOGEN INC
    Inventors: Ravi V.J. CHARI, Walter A. BLATTLER
  • Publication number: 20130108620
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 2, 2013
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Gail Colbern Schwall
  • Patent number: 8337856
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: December 25, 2012
    Assignee: Immunogen, Inc.
    Inventors: Walter Blättler, Ravi V. J. Chari
  • Publication number: 20120226025
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: IMMUNOGEN, INC.
    Inventors: Ravi V.J. CHARI, Wayne WIDDISON, Rita M. STEEVES, Walter A. BLATTLER
  • Patent number: 8198417
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 12, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Patent number: 8163888
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 24, 2012
    Assignee: Immunogen, Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Patent number: 8093358
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: January 10, 2012
    Assignee: Immunogen, Inc.
    Inventors: Walter Blättler, Ravi V. J. Chari
  • Patent number: 8088387
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: January 3, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blättler
  • Patent number: 7989598
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 2, 2011
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Publication number: 20100136033
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 3, 2010
    Applicant: IMMUNOGEN, INC.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Patent number: 7585857
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: September 8, 2009
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler
  • Patent number: 7575748
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Patent number: RE43899
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: January 1, 2013
    Assignee: Immunogen Inc.
    Inventors: Walter A. Blättler, Ravi V. J. Chari
  • Patent number: RE44704
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 14, 2014
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler